What were the key takeaways from Kestra Medical’s earnings call?

What is Kestra Medical's latest dividend and current dividend yield?

What factors drove the changes in Kestra Medical's revenue and profit?

Did Kestra Medical beat or miss consensus estimates last quarter?

What is Kestra Medical's gross profit margin?

What were the key takeaways from Kestra Medical's earnings call?

What guidance did Kestra Medical's management provide for the next earnings period?

What is the revenue and EPS growth rate for Kestra Medical year over year?

- **Revenue Acceleration**: Q3 2026 revenue up 63% YoY to $24.6M, with 58% prescription growth and 900+ new patients. 
- **Gross Margin Expansion**: 52.6% (up 900bps YoY), targeting 70%+ with scale. 
- **Market Leadership**: WCD market growing 15%+ vs 8% 12 months ago, with Kestra adding 50+ new sales reps. 
- **Strategic Innovations**: FDA-approved algorithm update reduces false alarms; Biobeat ABPM integration for 72% of ACE-PAS patients. 
- **Reimbursement Wins**: Florida Medicaid contracts, VA federal supply schedule, and 2% Medicare rate increase. 
- **Operational Efficiency**: 80%+ in-network rate, 46% conversion rate (vs 43% prior), and $9M Q3 CapEx for inventory growth.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2026 revenue of $24.6M, up 63% YoY, driven by 58% increase in prescriptions and 900+ new patients. Gross margin improved to 52.6% (up 900bps YoY). 
- **Market Expansion**: WCD market growing at low-mid teens (~15%), with Kestra gaining share in 100+ hospitals. 130 sales territories targeted by Q4 2026 (vs 80 in Q3 2025). 
- **Innovation**: FDA-approved ASSURE algorithm update reduces false alarms; Biobeat collaboration adds ABPM monitoring for 72% of ACE-PAS patients with hypertension. 
- **Reimbursement**: In-network rate 80%+ (vs 70% at IPO), with new Florida Medicaid contracts and VA federal supply schedule. Medicare reimbursement rate increased 2% to $3,589/month. 

**【CFO Financial Commentary】**
- **Q3 Results**: GAAP net loss $34.2M (vs $21.8M), adj. EBITDA loss $21.2M. Cash balance $291M post-December equity offering. 
- **Guidance**: FY2026 revenue raised to $93M (55% growth vs prior $91M). Gross margin expansion to 70%+ over next few years. 
- **Cost Management**: Sequential gross margin improvement for 9th straight quarter. Operating expenses $47.7M (including $1.5M non-recurring costs). 

**【Q&A Highlights】**
- **Market Growth**: WCD market growing 15%+ vs 8% 12 months ago, driven by clinical data (ACE-PAS) and Kestra's 50+ new sales reps. 
- **Sales Force**: 130 territories by Q4 2026 (vs 100 in Q3 2025). 70% of new prescriptions from existing accounts, 30% from new prescribers. 
- **Gross Margin**: 52.6% in Q3, targeting 70%+ with scale. $9M Q3 CapEx for inventory, aligning with 10% new units/90% reconditioning model. 
- **VA Expansion**: Federal supply schedule enables access to 9M VA patients. Early wins in Florida VA hospitals. 
- **Conversion Rate**: 46% in Q3 (vs 43% prior), improving due to better RCM and in-network rates. 
- **Competitive Landscape**: Incumbent Zoll launching new WCD but slow adoption. Kestra's ASSURE system has 100% arrhythmia conversion rate vs Zoll's 85%.

KESTRA MEDICAL TECHNOLOGIES, LTD.(KMTS)-20260318-2026 Q3 Earnings call transcript

- **Revenue Milestone**: Q2 2026 revenue of $22.6M (+53% YoY), gross margin surpasses 50% for first time at 50.6%.
- **Clinical Validation**: ACE-PAS study confirms ASSURE system safety (1.8% SCA incidence rate), wearability (23.1 hours), and low false alarms (94% patients).
- **Market Growth**: WCD market expanding at low double digits, with Kestra gaining share (13% of market vs. competitor's 5% growth).
- **Updated Guidance**: FY2026 revenue raised to $91M (+52% YoY), fueled by 80%+ in-network mix and 48.8% conversion rate.
- **Long-Term Vision**: Targeting 70%+ gross margins through scale, with 90% of fittings via device reuse by FY2028.

**【CEO Opening Remarks】**
- CEO Brian Webster highlighted Q2 2026 revenue of $22.6 million, a 53% YoY increase, driven by 54% growth in prescriptions. Gross margin reached 50.6%, an 11-point improvement YoY, marking the first time above 50%.
- The ASSURE system met both primary endpoints in the ACE-PAS study, demonstrating safety and effectiveness. Key results included a 90-day SCA incidence rate of 1.8%, 23.1-hour wear time, and 94% patients free of false alarms.
- The WCD market is underpenetrated (14% of eligible patients), with Kestra targeting 70%+ gross margins over the next few years through scale and in-network payer expansion.

**【CFO Financial Commentary】**
- Q2 GAAP net loss was $32.8 million, with adjusted EBITDA loss of $19.7 million. Cash reserves totaled $175.4 million, plus $148 million from a recent equity offering.
- Updated FY2026 revenue guidance raised to $91 million (52% YoY growth), driven by in-network mix (now low 80s) and operating leverage.
- Conversion rate improved to 48.8%, up from 48.2% in Q2 2025, reflecting stronger revenue cycle management.

**【Q&A Highlights】**
- **Market Growth & Share**: CEO noted WCD market growing at low double digits, with Kestra gaining share (13% of market vs. competitor's 5% growth). Conversion rate of 48.8% vs. competitor's ~60% indicates opportunity.
- **Clinical Guidelines**: ACE-PAS data may influence future updates to 2017 guidelines, with clinicians now recognizing higher patient risk levels early in recovery.
- **Sales Expansion**: Sales force expanded to 100 reps (from 80 in Q2 2025), with plans to accelerate hiring based on equity proceeds. Clinical specialists added to support high-volume accounts.
- **Gross Margin Trajectory**: CFO expects steady expansion to 70%+ over next few years, driven by device reuse (90% of fittings by FY2028) and scale economies.
- **New Product Pipeline**: CEO hinted at innovation across WCD, wearable, and digital platforms, using ACE-PAS data to identify unmet needs.


Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q1 2026 revenue up 52% YoY to $19.4M, driven by 51% prescription growth. 
- **Gross Margin Expansion**: 45.7% (vs. 32.9% prior year), on track for 70%+ in a few years. 
- **Clinical Validation**: Late-breaking AHA study to present 25,000-patient data, solidifying compliance and safety leadership. 
- **Market Opportunity**: 6x underserved patients in $1B+ WCD market. 
- **Operational Efficiency**: 80% in-network mix, 47% conversion rate, and $201M cash runway.

**【CEO Summary Section】**
- Q1 2026 revenue reached $19.4 million, up 52% YoY, driven by 51% YoY increase in prescriptions (4,200+ ASSURE system prescriptions). 
- Gross margin expanded to 45.7% (vs. 32.9% prior year), with 7 consecutive quarters of margin improvement. 
- Key growth drivers: 
  1. Sales expansion (80+ territories, targeting high-WCD geographies) 
  2. RCM improvements (in-network mix 80% vs. 70% at IPO) 
  3. Fleet scale (3 patient wears/device/year) 
  4. Clinical evidence (FDA post-approval study enrollment complete)
- WCD market penetration at ~14%, with 6x underserved patients. Late-breaking AHA study will present 25,000-patient data on compliance, safety, and outcomes.

**【CFO Financial Commentary】**
- Q1 GAAP net loss: $25.8M (vs. $20.3M prior year). Adjusted EBITDA loss: $19.4M (vs. $15.7M). 
- FY26 revenue guidance raised to $88M (47% YoY growth). 
- Conversion rate 47% (vs. 40% prior year), driven by: 
  - 20% cost per fit decline 
  - 20% revenue per fit increase 
  - 80% in-network mix (vs. 70% at IPO)
- Cash reserves: $201.2M, with $15M available under term loan. 
- Targeting 70%+ gross margins through scale and volume leverage.

**【Q&A Highlights】**
- **Prescription Growth**: Sequential +300 prescriptions, annualizing to ~14% market share. 
- **In-Network Strategy**: Focused on 3,000+ payers, prioritizing high-WCD geographies. 
- **Compliance**: Median daily wear >23 hours, sustained adherence >90 days. 
- **Competitive Position**: Incumbent competitor's SCD PROTECT study validates WCD need, but Kestra offers superior compliance and outcomes. 
- **OpEx Cadence**: Steady territory expansion with ~50% U.S. coverage, targeting 100% over time.

Kestra Medical Technologies, Ltd. (KMTS) Q1 2026 Earnings Call Transcript

- **Revenue Surge**: Q4 FY25 revenue up 71% YoY to $17.2M, FY25 total $59.8M (115% YoY growth). 
- **Gross Margin Soars**: Q4 gross margin 44.3% (vs. 13.9% prior year), FY25 margin 40.5% (vs. 1.3% FY24). Targeting 70%+ by 2026.
- **Market Expansion**: 80 sales territories (67% YoY growth), 285M+ in-network patients, 43% prescription increase.
- **Clinical Superiority**: ASSURE false alarm rate 6% (vs. 46% competitor), 23.2-hour daily wear, 96% shock efficacy.
- **2026 Outlook**: $85M revenue (42% growth), 40%+ prescription growth, 70%+ in-network mix, $40M+ stock comp expenses.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 FY25 revenue of $17.2M, up 71% YoY, driven by 43% increase in prescriptions (3,900+ ASSURE system prescriptions). FY25 total revenue $59.8M, up 115% YoY.
- **Gross Margin Expansion**: Q4 FY25 gross margin 44.3% (vs. 13.9% prior year), FY25 gross margin 40.5% (vs. 1.3% FY24). Targeting 70%+ gross margin over next few years.
- **Market Penetration**: 80 sales territories as of FY25 end (up 67% YoY), with plans to nearly double coverage over next few years. In-network payer coverage now exceeds 285M U.S. health plan members.
- **Clinical Evidence**: ASSURE system false alarm rate 6% (vs. 46% competitor), median daily wear 23.2 hours. Post-approval registry of 20,000+ patients shows 96% shock conversion efficacy.
- **Innovation**: Over 365 patent assets; investing in R&D for next-gen cardiac recovery systems and new therapeutic capabilities.

**【CFO Financial Commentary】**
- **Q4 FY25 Financials**: GAAP net loss $51.1M (vs. $22.3M prior year), adjusted EBITDA loss $20.3M (vs. $16.5M). FY25 GAAP net loss $113.8M, adjusted EBITDA loss $68.4M.
- **Revenue Conversion**: Q4 revenue conversion rate 44.8%, FY25 rate 46.8% (excluding one-time items). Driven by higher in-network patient mix (70%+ of new fits) and cost improvements.
- **2026 Guidance**: Revenue $85M (42% YoY growth), driven by 40%+ prescription growth and 70%+ in-network patient mix. Expect $40M+ in stock-based compensation expenses.
- **Cash Position**: $237.6M as of April 30, 2025, supporting growth investments.

**【Q&A Key Highlights】**
- **Sole-Source Contract**: Signed with risk-bearing provider network for streamlined patient care and reduced hospital readmissions. Highlights ASSURE's clinical differentiation.
- **Conversion Rate Drivers**: Focus on high-prescription, high-in-network territories. Targeting 76% best-in-class conversion rate (currently 46.8%).
- **Competitive Landscape**: Competitor maintains 86% market share but ASSURE gaining traction via superior comfort, compliance, and clinical outcomes.
- **Operating Leverage**: 40%+ revenue growth vs. 20%+ OpEx growth, enabling gross margin expansion and R&D investments.
- **Innovation Pipeline**: Next-gen ASSURE system and new therapeutic capabilities in development, with clinical data expected to support guideline changes.

Actual	-1.25	-2.21	-0.5	-0.64	-0.61
Forecast	-0.6033	-0.525	-0.61	-0.5941	-0.5961
Surprise	-107.19%	-320.95%	+18.03%	-7.73%	-2.33%

Actual	15.09M	17.23M	19.37M	22.57M	24.55M
Forecast	15.07M	15.67M	17.87M	20.72M	22.87M
Surprise	+0.12%	+9.99%	+8.42%	+8.93%	+7.35%

KMTS

KMTS fundamentals

KMTS Q3 2026 Earnings

Earnings Call

You can ask Aime

KMTS

KMTS fundamentals

KMTS Q3 2026 Earnings

Earnings Call

KMTS Earnings Call Summary for Q3/20264:30 PM on Mar 17, 2026

KMTS Earnings Call Summary for Q2/20264:30 PM on Dec 11, 2025

KMTS Earnings Call Summary for Q1/20267:00 AM on Sep 11, 2025

KMTS Earnings Call Summary for Q4/20254:30 PM on Jul 15, 2025

KMTS Earnings Call Summary for Q3/20254:30 PM on Apr 14, 2025

You can ask Aime